UniPharma Co., Ltd.
UniPharma Co., Ltd. engages in the distribution of pharmaceutical drugs, medical devices, and diagnostic tests in Taiwan. It provides diagnostic tests in areas of oncology, gynecology, orthopedics, neurology, anesthesiology, and cardiology. The company offers Adept reduction solution; bain, esmolol HCI, and naloxone anesthesia injections; Elisa DR-70 test for in-vitro diagnostics of tumors; and f… Read more
UniPharma Co., Ltd. (6621) - Total Assets
Latest total assets as of June 2025: NT$291.61 Million TWD
Based on the latest financial reports, UniPharma Co., Ltd. (6621) holds total assets worth NT$291.61 Million TWD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
UniPharma Co., Ltd. - Total Assets Trend (2019–2024)
This chart illustrates how UniPharma Co., Ltd.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
UniPharma Co., Ltd. - Asset Composition Analysis
Current Asset Composition (December 2024)
UniPharma Co., Ltd.'s total assets of NT$291.61 Million consist of 60.8% current assets and 39.2% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 17.8% |
| Accounts Receivable | NT$16.86 Million | 5.1% |
| Inventory | NT$22.27 Million | 6.8% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$3.58 Million | 1.1% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how UniPharma Co., Ltd.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: UniPharma Co., Ltd.'s current assets represent 60.8% of total assets in 2024, an increase from 56.2% in 2019.
- Cash Position: Cash and equivalents constituted 17.8% of total assets in 2024, down from 44.0% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, a decrease from 16.0% in 2019.
- Asset Diversification: The largest asset category is inventory at 6.8% of total assets.
UniPharma Co., Ltd. Competitors by Total Assets
Key competitors of UniPharma Co., Ltd. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
UniPharma Co., Ltd. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - UniPharma Co., Ltd. generates 0.28x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - UniPharma Co., Ltd. is currently not profitable relative to its asset base.
UniPharma Co., Ltd. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.19 | 11.05 | 7.90 |
| Quick Ratio | 5.30 | 9.65 | 7.08 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$162.15 Million | NT$ 173.23 Million | NT$ 217.38 Million |
UniPharma Co., Ltd. - Advanced Valuation Insights
This section examines the relationship between UniPharma Co., Ltd.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.71 |
| Latest Market Cap to Assets Ratio | 0.03 |
| Asset Growth Rate (YoY) | -6.0% |
| Total Assets | NT$328.98 Million |
| Market Capitalization | $10.99 Million USD |
Valuation Analysis
Below Book Valuation: The market values UniPharma Co., Ltd.'s assets below their book value (0.03 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: UniPharma Co., Ltd.'s assets decreased by 6.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for UniPharma Co., Ltd. (2019–2024)
The table below shows the annual total assets of UniPharma Co., Ltd. from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$328.98 Million | -6.03% |
| 2023-12-31 | NT$350.07 Million | +5.26% |
| 2022-12-31 | NT$332.57 Million | -4.48% |
| 2021-12-31 | NT$348.18 Million | -16.22% |
| 2020-12-31 | NT$415.57 Million | -8.90% |
| 2019-12-31 | NT$456.14 Million | -- |